Immunostimulation with intrapleural bcg as adjuvant therapy in resected non-small cell lung cancer
1986; Wiley; Volume: 58; Issue: 11 Linguagem: Inglês
10.1002/1097-0142(19861201)58
ISSN1097-0142
Tópico(s)Immunotherapy and Immune Responses
ResumoCancerVolume 58, Issue 11 p. 2411-2416 ArticleFree Access Immunostimulation with intrapleural bcg as adjuvant therapy in resected non-small cell lung cancer† First published: 1 December 1986 https://doi.org/10.1002/1097-0142(19861201)58:11 3.0.CO;2-CCitations: 19 † The Ludwig Lung Cancer Study Group (LLCSG) AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract A prospective randomized trial was performed to evaluate the role of adjuvant local immunostimulation with bacillus Calmette-Guérin (BCG) in resected Stage I and Stage II non-small cell bronchogenic carcinoma. The patients were stratified according to extent of resection and surgical stage, and randomized to treatment or placebo. Adjuvant treatment consisted of a single dose of BCG (Tice) injected into the pleural space between days 6 and 12 postoperatively. Isoniazid was given by mouth for 12 weeks. In the control group saline was injected intrapleurally. Of 441 patients included in the study, 407 were evaluable, 198 of them in the BCG group and 209 in the control group. The average follow-up was 4.7 years. A high rate of complications was noted in the BCG group; after pneumonectomy 22% of these patients developed pleural empyema necessitating further surgical procedures, in comparison with 3% in the placebo group. There was no significant difference between the two randomized groups with respect to survival. There was, however, a significant decrease in the disease-free interval in patients who received BCG (P = 0.044). This detrimental effect with BCG was especially pronounced in pneumonectomized patients (P = 0.028). There was no significant difference between treatment and placebo in patients with lobectomies. Because of no proved benefit of regional administration of BCG (and even of detrimental effects after pneumonectomy) and a high rate of severe complications, the authors advise against the use of BCG intrapleurally as local adjuvant immunostimulation. References 1 Selawry OS, Hansen HH. Lung cancer. In: JF Holland, E Frei, eds. Cancer Medicine. Philadelphia: Lea & Febiger, 1982; 1709. Google Scholar 2 L Israel, AP Chaninian, eds. Lung Cancer: Natural History, Prognosis and Therapy. New York: Academic Press, 1976; 128–129. Google Scholar 3 Ruckdeschel JC, Codish SD, Stranaham A, McKneally MF. Postoperative empyema improves survival in lung cancer: documentation and analysis of a natural experiment. N Engl J Med 1972; 287: 1013–1017. 10.1056/NEJM197211162872004 CASPubMedWeb of Science®Google Scholar 4 McKneally MF, Maver C, Kausel HW, Alley RD. Regional immunotherapy with intrapleural BCG in lung cancer. Lancet 1976; 1: 377–379. 10.1016/S0140-6736(76)90212-9 CASPubMedWeb of Science®Google Scholar 5 McKneally MF, Maver C, Lininger L, Kausel HW, McIlduff JB, Oder TM, Foster EF, Alley RD. Four-year follow-up of the Albany experience with intrapleural BCG in lung cancer. J Thorac Cardiovasc Surg 1981; 81: 485–492. CASPubMedWeb of Science®Google Scholar 6 Lowe J, Shore DF, Iles PB, Langmann MJS, Baldwin RW. Intrapleural BCG in operable lung cancer. Lancet 1980; 1: 11–14. 10.1016/S0140-6736(80)90551-6 CASPubMedWeb of Science®Google Scholar 7 National Lung Cancer Study Group. Surgical adjuvant immunotherapy in non-oat cell carcinoma. In: W Terry, S Rosenberg, eds. Immunotherapy of Cancer: Present Status of Trials in Man. New York: Elsevier, 1982; 104–110. Google Scholar 8 Gail MH, Oldham RK, Holmes EC et al. Early side effects of in-trathoracic BCG therapy in patients with Stage I squamous cell carcinoma, adenocarcinoma, or large-cell carcinoma. Cancer Immunol Immunother 1981; 10: 129–137. 10.1007/BF00205884 Web of Science®Google Scholar 9 Oldham RK, Gail MH, Baker MA et al. and the Lung Cancer Study Group. Immunological studies in a double blind randomized trial comparing intrapleural BCG against placebo in patients with resected stage I non-small cell lung cancer. Cancer Immunol Immunother 1982; 13: 164–173. 10.1007/BF00205382 CASPubMedWeb of Science®Google Scholar 10 Gail MH, Eagan RT, Feld R et al. and the Lung Cancer Study Groupm. Prognostic factors in patients with resected stage I non-small cell lung cancer: A report from the Lung Cancer Study Group. Cancer 1984; 54: 1802–1813. 10.1002/1097-0142(19841101)54:9 3.0.CO;2-4 CASPubMedWeb of Science®Google Scholar 11 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481. 10.1002/cncr.21979 CASWeb of Science®Google Scholar 12 Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 1977; 35: 7–11. 10.1038/bjc.1977.1 Web of Science®Google Scholar 13 Fisher RA. The logic of inductive inference. J R Stat Soc 1935; 98: 39–54. 10.1111/j.2397-2335.1935.tb04208.x Web of Science®Google Scholar 14 Broder S, Waldmann TA. The suppressor-cell network in cancer. N Engl J Med 1978; 299: 1335–1341. 10.1056/NEJM197812142992404 CASPubMedWeb of Science®Google Scholar 15 Jansen HM, The TH, Orie NGM. Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma. Thorax 1980; 35: 781–787. 10.1136/thx.35.10.781 CASPubMedWeb of Science®Google Scholar 16 Edwards FR. Use of BCG as an immunostimulant after resection of carcinoma of the lung: A two-year assessment of a trial of 500 patients. Thorax 1979; 34: 501–506. 10.1136/thx.34.6.801 PubMedWeb of Science®Google Scholar 17 Eliber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 1970; 25: 362–366. 10.1002/1097-0142(197002)25:2 3.0.CO;2-V PubMedGoogle Scholar 18 Holmes EC, Golub SH. Immunologic defects in lung cancer patients. J Thorac Cardiovasc Surg 1976; 71: 161–168. CASPubMedWeb of Science®Google Scholar 19 Wright P, Hill L, Peterson A. Adjuvant immunotherapy for lung cancer. In: S Jones, S Salmon, eds. Adjuvant Therapy of Cancer II. New York: Grune & Stratton Press, 1979; 545–552. Web of Science®Google Scholar 20 Zwilling BS, Davis GW. Effect of Bacillus Calmette-Guerin on the development of primary lung cancer in Syrian gold hamsters. Cancer Res 1980; 40: 3455–3458. CASPubMedWeb of Science®Google Scholar 21 Giuliano AE, Rangeo DM, Golub SH, Holmes EC, Morton DL. Serum-mediated immunosuppression in lung cancer. Cancer 1979; 43: 917–924. 10.1002/1097-0142(197903)43:3 3.0.CO;2-3 CASPubMedWeb of Science®Google Scholar 22 Gross NJ, Eddie-Quartey A. Immune status in lung cancer: Effects of BCG immunotherapy. Am Rev Resp Dis 1976; 113: 457–464. CASPubMedWeb of Science®Google Scholar 23 Holmes EC, Ramming KP, Bein ME, Coulson WF, Callery CD. Intralesional BCG immunotherapy of pulmonary tumors. J Thorac Cardiovasc Surg 1979; 77: 362–368. CASPubMedWeb of Science®Google Scholar 24 Allen EM, Moore VL, Stevens JO. Strain variation in BCG induces chronic pulmonary inflammation in mice: I. Basic model and possible genetic control by non-H-2 genes. J Immunol 1977; 119: 343–347. CASPubMedWeb of Science®Google Scholar 25 Baker MA, Taub RN. Comparison of the adjuvant effect of 3 BCG preparations in mice. Oncology 1978; 35: 214–216. 10.1159/000225289 CASPubMedWeb of Science®Google Scholar 26 Bast RC Jr, Zbar B, Borsos T, Rapp HJ. BCG and cancer. N Engl J Med 1974; 290: 1413–1420. 10.1056/NEJM197406202902506 PubMedWeb of Science®Google Scholar 27 Israel L, Mugica J, Chahinian AP. Prognosis of early bronchogenic carcinoma: Survival curves of 451 patients after resection of lung cancer in relation to the results of the preoperative tuberculin skin test. Biomed 1973; 19: 68–72. CASPubMedWeb of Science®Google Scholar 28 Mitchel MS, Kirkpatrick D, Mokyr MB, Gery I. On the mode of action of BCG. Nature 1973; 243: 216–218. Google Scholar 29 Pouillart P, Mathe G, Valangie T et al. Trial of BCG immunotherapy in the treatment of resectable squamous cell carcinoma of the bronchus (Stage I and II). Cancer Immunol Immunother 1976; 1: 271–273. 10.1007/BF00200104 Web of Science®Google Scholar 30 Rescoe P, Pearce S, Ludgate S, Home NW. A control trial of BCG immunotherapy in bronchogenic carcinoma treated by surgical resection. Cancer Immunol Immunother 1977; 3: 115–118. Google Scholar 31 Ludwig Lung Cancer Study Group. Adverse reactions to intra-pleural BCG (Letter) N Engl J Med 1981; 305: 167–168. 10.1056/NEJM198107163050313 Google Scholar 32 Law MR, Lam WK, Studdy PR, Pugsley WB, Hodson ME. Complications of intrapleural BCG in the treatment of operable non-small cell bronchial carcinoma. Br J Dis Chest 1982; 76: 151–156. 10.1016/0007-0971(82)90027-4 CASPubMedWeb of Science®Google Scholar 33 MacKaness GB, Auclair DJ, LaGrange PH. Immuno-potentiation with BCG: 1. Immuneresponse to different strains and preparations. J Natl Cancer Inst 1973; 51: 1655. CASPubMedWeb of Science®Google Scholar 34 Gutterman JO, Mavligit G, McBride C, Frei E, Freireich EJ, Hersh EM. Active immunotherapy with BCG for recurrent malignant melanoma. Lancet 1973; 1: 1208. 10.1016/S0140-6736(73)90526-6 CASPubMedWeb of Science®Google Scholar 35 Lowe J, Iles PB, Shore DF, Langman MJS, Baldwin RW. Intrapleural BCG in operable lung cancer. Lancet 1980; 1: 11–14. 10.1016/S0140-6736(80)90551-6 CASPubMedWeb of Science®Google Scholar 36 Millar JW, Roscoe P, Pearce SJ, Ludgate S, Horne NW. Five year results of a controlled study of BCG immunotherapy after surgical resection in bronchogenic carcinoma. Thorax 1982; 37: 57–60. 10.1136/thx.37.1.57 CASPubMedWeb of Science®Google Scholar 37 Fon GT, Bein ME, Holmes EC, Huberman RP. Intralesional BCG injection of pulmonary neoplasms: radiographic findings. AJR 1981; 137: 269–275. 10.2214/ajr.137.2.269 CASPubMedWeb of Science®Google Scholar 38 Bakker W, Nijhuis-Heddes JMA, Brutel de la Riviere A, Dijkman JH. Complications of postoperative intrapleural BCG in lung cancer. Ann Thorac Surg 1982; 33: 267–272. 10.1016/S0003-4975(10)61923-6 CASPubMedWeb of Science®Google Scholar 39 Bennett JA, McKneally MF. Intrapleural Bacillus Calmette-Guérin administration (Letter) Ann Thorac Surg 1982; 34: 477. 10.1016/S0003-4975(10)61421-X CASPubMedWeb of Science®Google Scholar 40 Roeslin N, Lang JM, Morand G, Wihlm JM, Witz JP. Regional immunotherapy in resected squamous cell lung carcinoma: Analysis of a randomized study. Cancer Immunol Immunother 1982; 13: 174–175. 10.1007/BF00205383 CASPubMedWeb of Science®Google Scholar 41 Ludwig Lung Cancer Study Group. Adverse effect of intrapleural corynebacterium paryum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1985; 89: 842–847. PubMedGoogle Scholar Citing Literature Volume58, Issue111 December 1986Pages 2411-2416 ReferencesRelatedInformation
Referência(s)